Tectonic Therapeutic: Interesting CV Disease Drug Developer [Seeking Alpha]
Tectonic Therapeutic, Inc. (TECX)
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Summary Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027. Despite early-stage development and competition from AstraZeneca, TECX is promising, with strong support from Wells Fargo and a long cash runway. J Studios/DigitalVision via Getty Images Tectonic Therapeutic ( NASDAQ: TECX ) went up over 100% on positive phase 1 data of its lead candidate TX45 targeting Group 2 Pulmonary Hypertension in patients with heart failure with preserved ejection fraction (HFpEF), or PH-LHD. That About the TPT service Thanks for reading.
Show less
Read more
Impact Snapshot
Event Time:
TECX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECX alerts
High impacting Tectonic Therapeutic, Inc. news events
Weekly update
A roundup of the hottest topics
TECX
News
- Tectonic Therapeutic (NASDAQ: TECX) is now covered by analysts at Raymond James. They set an "outperform" rating and a $65.00 price target on the stock.MarketBeat
- Tectonic Therapeutic Inc. Reports Q3 2024 Results [Yahoo! Finance]Yahoo! Finance
- Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Wells Fargo & Company from $55.00 to $79.00. They now have an "overweight" rating on the stock.MarketBeat
- Tectonic Therapeutic (NASDAQ: TECX) had its price target raised by analysts at Leerink Partners from $49.00 to $69.00. They now have an "outperform" rating on the stock.MarketBeat
- Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion ProteinGlobeNewswire
TECX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/7/24 - Form 8-K
- TECX's page on the SEC website